DES

Across TCGA pan-cancer cohorts, DES Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated DES data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher DES Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DES expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

ACC, HNSC, and LIHC are the cancer types where DES Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
HNSC	OS	Median	III,IV	0.051	0.726	<.001	39	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
GBM	DFS	Median	All	0.067	0.244	.011	3	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →
LUSC	DFS	Median	All	0.832	0.369	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

DES–ACC (DFS)

Open the ACC breakdown →